key: cord-0702888-zwwin40x
authors: Terpos, Evangelos; Trougakos, Ioannis P.; Gavriatopoulou, Maria; Papassotiriou, Ioannis; Sklirou, Aimilia D.; Ntanasis-Stathopoulos, Ioannis; Papanagnou, Eleni-Dimitra; Fotiou, Despina; Kastritis, Efstathios; Dimopoulos, Meletios A.
title: Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
date: 2021-04-22
journal: Blood
DOI: 10.1182/blood.2021011904
sha: c564ed1c271b315df095b5e31a84764f4fea93a8
doc_id: 702888
cord_uid: zwwin40x

nan

Patients with multiple myeloma (MM) are at increased risk of infections due to their immunocompromised state, old age and comorbidities. 1 Coronavirus disease 2019 (COVID-19) causes moderate to severe acute respiratory dysfunction in 77% of MM patients and leads to critical condition approximately 8% of them. 2 More than 80% of MM patients who are infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require hospital admission, 3 while almost 33% of hospitalized MM patients with COVID-19 may die because of the infection 4 . This is mainly due to the limited therapeutic options for COVID-19 available to-date. 5 Vaccination against SARS-CoV-2 could be an important preventive strategy against COVID-19 for MM patients, but its efficacy in MM is largely unknown. 6 The BNT162b2 mRNA vaccine is the first approved anti-SARS-CoV-2 vaccine by both US Food and Drug Administration and European Medicines Agency due to its high efficacy in apparently healthy adults. 7 Recently, it was reported that the first BNT162b2 dose provided some protection against COVID-19 among nursing facility members. 8, 9 However, there is no information in the literature for the efficacy of BNT162b2 vaccine in patients with MM or with other malignant diseases. Herein, we report the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in MM patients after the first dose of the BNT162b2 vaccine.

Major inclusion criteria for the participation of MM patients in this study included: (i) age Interestingly, only one (11.1%) out of nine patients with smoldering myeloma had NAb titers of equal or more than 30% (positivity cut-off) versus 11/39 (28.2%) patients with active MM.

This patient had normal levels of the univolved immunoglobulins, while the other eight patients had immunoparesis in at least one uninvolved immunoglobulin. This observation is of great interest as hypoglobulinemia has been associated with inferior antibody response among patients with chronic lymphocytic leukemia and COVID-19. 12 Our data indicate that the first dose of BNT162b2 leads to production of lower levels of NAbs against SARS-CoV-2 compared to non-MM controls of similar age and gender and without malignant disease. This may be due to the effect of myeloma cells which suppress normal B-cell expansion and immunoglobulin production. Furthermore, some anti-myeloma therapies have a B-cell depleting activity which in turn may impair immune response to vaccines, whereas both myeloma microenvironment and anti-myeloma treatments may impair T-cell function. 13 Patients with MM often present suboptimal seroconversion rates after a single-dose vaccine against bacteria and viruses and, therefore, booster doses are needed to assure adequate protection, such as in the case with the seasonal flu vaccine. 13 We should also take into consideration that the production of NAb titers against SARS-CoV-2 at a level of ≥50% on D21 after the first BNT162b2 dose has been low, even among healthy individuals aged 65-85 years. 11 However, higher antibody titers after a single dose of mRNAbased vaccine against SARS-CoV-2 have been detected in individuals who have recovered from COVID-19. 9 Since our results indicate that elderly myeloma patients have a blunted antibody response after the first vaccine dose, they also suggest that the administration of a second timely vaccine dose is essential for this elderly subpopulation, with a malignant hematological disease that deregulates the immune homeostasis, to develop an adequate antibody-based immune response. Anti-myeloma therapy seems to negatively affect the NAb production (after a single dose), although higher patient numbers are needed to evaluate the effects of specific anti-myeloma regimens on the immune responses of anti-SARS-CoV-2 vaccination. Furthermore, this low antibody response of elderly myeloma patients after the first BNT162b2 dose may not be seen in younger patients. Our ongoing study will answer this question also. 

Abbreviations: PI: proteasome inhibitor; IMiD: immunomodulatory drug; VRD, bortezomib, lenalidomide and dexamethasone; IRD, ixazomib, lenalidomide and dexamethasone; PomVD: pomalidomide, bortezomib and dexamethasone; Rd, lenalidomide and dexamethasone; R, lenalidomide; RCD, lenalidomide, cyclophosphamide and On D22, myeloma patients had lower production of NAb inhibition titers compared to controls of similar age and gender (see text). Only four myeloma patients had NAb titers of equal or more than 50%.

A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Emerging treatment strategies for COVID-19 infection

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network